Macrogenics INC Form 4 insider transactions

Director Jay Philip Siegel reports the vesting and disposal of 4,500 restricted stock units (RSUs) of Macrogenics Inc. on May 20, 2024.

Director William K. Heiden reports the vesting and disposal of 4,500 restricted stock units (RSUs) of Macrogenics Inc. on May 20, 2024.

Director Scott Thomas Jackson reports the vesting and disposal of 4,500 restricted stock units (RSUs) of Macrogenics Inc. on May 20, 2024.

Director David C. Stump reports the vesting and disposal of 4,500 restricted stock units (RSUs) of Macrogenics Inc. on May 20, 2024.

Director Federica F. O'Brien reports the vesting and disposal of 4,500 restricted stock units (RSUs) of Macrogenics Inc. (MGNX) on May 20, 2024.

Director Margaret Liu reports the vesting and disposal of 4,500 restricted stock units (RSUs) of Macrogenics Inc. on May 20, 2024.

Director Meenu Chhabra reports a transaction involving the acquisition and disposal of common stock units of Macrogenics Inc. on May 20, 2024, related to vested restricted stock units.

Director Karen Jean Ferrante reports the vesting and disposal of 4,500 restricted stock units (RSUs) of MacroGenics Inc. on May 20, 2024.

Director Edward Hurwitz reports the vesting of restricted stock units (RSUs) into common stock of Macrogenics Inc.

Senior VP and General Counsel of MacroGenics, Jeffrey Stuart Peters, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

Jeffrey Stuart Peters, Senior VP and General Counsel of Macrogenics, Inc., executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Eric Blasius Risser, Chief Operating Officer of MacroGenics, Inc., exercised stock options and sold shares of common stock under a pre-arranged trading plan.

Thomas Spitznagel, a Senior VP at Macrogenics, exercised stock options and sold 10,000 shares of common stock on March 4, 2024, according to a Form 4 filing.

James Karrels, SVP, CFO and Secretary of Macrogenics Inc, sold 30,000 shares of common stock on March 4, 2024, at a price of $20.5 per share.

Jeffrey Stuart Peters, Senior VP and General Counsel of MacroGenics Inc., sold 16,124 shares of common stock at an average price of $17.22 on February 26, 2024, under a pre-arranged 10b5-1 trading plan.